Alto Neuroscience (NYSE:ANRO) Trading Down 6.4% – Here’s Why

by · The Markets Daily

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) shares fell 6.4% on Tuesday . The company traded as low as $26.24 and last traded at $26.2790. Approximately 290,790 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 329,169 shares. The stock had previously closed at $28.07.

Analysts Set New Price Targets

ANRO has been the subject of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Wolfe Research initiated coverage on Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating for the company. Bank of America began coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price on the stock. Robert W. Baird cut their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.25.

View Our Latest Analysis on Alto Neuroscience

Alto Neuroscience Trading Down 6.4%

The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The business has a fifty day simple moving average of $22.82 and a 200 day simple moving average of $20.36. The stock has a market cap of $921.99 million, a price-to-earnings ratio of -10.86 and a beta of 1.24.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities analysts anticipate that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Institutional Trading of Alto Neuroscience

A number of hedge funds have recently bought and sold shares of ANRO. Torren Management LLC acquired a new position in Alto Neuroscience in the 4th quarter valued at $62,000. Balyasny Asset Management L.P. purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at $198,000. OMERS ADMINISTRATION Corp acquired a new position in Alto Neuroscience in the fourth quarter valued at $221,000. Charles Schwab Investment Management Inc. purchased a new position in Alto Neuroscience during the fourth quarter worth about $304,000. Finally, Revisor Wealth Management LLC acquired a new stake in Alto Neuroscience in the 1st quarter worth about $385,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

See Also